The shareholders of
With regards to the risks related to the spread of the Coronavirus (COVID-19),
· No food or drink will be served.
· Participation by both Board of Directors and Management will be restricted.
· The duration of the General Meeting will be reduced, but without infringing on the rights of the shareholders.
· A shorter presentation will be held by the CEO.
Prior to the General Meeting,
Right to attend the Meeting
Shareholders who wish to attend the meeting, must
1. be registered the share register maintained by
2. also to register with
Nominee-registered shares
To be entitled to participate in the Meeting, shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names in the share.
Proxy
Shareholders represented by proxy must submit a dated power of attorney. If the power of attorney is executed by a legal person, a certified copy of the certificate of registration or equivalent must be attached. The power of attorney may not be valid for a longer period than five years from its issuance. A copy of the power of attorney and certification should be submitted to the Company by post at the address mentioned above in duly time prior to the Meeting. Power of attorney in original and registration certificate must also be presented at the AGM. The form for power of attorney will be available via the Company's website, www.bioservo.se, and sent free of charge to the
the shareholders who request it and state their postal address.
Annual report
The annual report and the auditor's report will be available on the Company's website www.bioservo.com on
Proposed Agenda
1. Opening of the Meeting
2. Appointment of chairman of the Meeting
3. Preparation and approval of the voting list
4. Election of one or two persons to approve the minute
5. Approval of the agenda
6. Determination that the Meeting has been duly convened
7. Submission of the annual accounts and the auditor
8. Resolution regarding:
a) the adoption of the income statement and the balance sheet
b) appropriation of the Company's results in accordance with the adopted balance sheet
c) discharge of the members of the board of directors and the managing director from liability
9. Determination of fees for members of the board of directors and auditors
10. Election of members of board of directors and election of auditor
11. The board of directors' proposal regarding authorization for the board of directors to resolve on issue of new shares
12. Closing of the Meeting
Proposed for decision
Election of chairman of the meeting (2)
Fees to the Board and auditors (9)
The Board of Directors proposes that unchanged annual fees be paid to the Board of Directors of
Election of members of board of directors and election of auditor (10)
The nomination committee proposes that the number of Board members on the Board should be six (6). The Nomination Committee proposes, for the period until the end of the next Annual General Meeting, re-election of the Board members
Proposal to re-elect auditor
Authorization for the board of directors to resolve on issue of new shares (11)
The Board of Directors proposes that the Meeting authorizes the Board of Directors to, for the period until the next Annual General Meeting, on one or more occasions, decide on a new issue of a maximum of 1,500,000 shares. The issue may be made with or without deviation from the shareholders' preferential rights and against cash payment, payment by kind, by set-off or otherwise with terms according to Chapter 2. Section 5, second paragraph, 1-3 and 5 the Swedish Companies Act. The purpose of the authorization is for the Company to be able to issue shares to enable payment of the purchase price when acquiring a company or business and to be able to make targeted issues with a view to acquiring capital for the Company. If the authorization is exercised in its entirety, this will correspond to a dilution of approximately 10.5% of the shares and votes in the Company. For decisions according to the Board's proposal, it is required that the AGM's decision be assisted by shareholders representing at least two-thirds of both the votes cast and the shares represented at the Meeting.
Number of shares and votes
The total number of shares and votes in the Company as of the date of the notice amounts to 14,298,321, each share having one vote. The company does not hold any own shares on the day of this notice.
Kista,
The board of directors
About
The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength.
For more information, please visit www.bioservo.com
https://news.cision.com/bioservo-technologies-ab--publ-/r/reviewing-notice-to-annual-general-meeting-in-bioservo-technologies-ab--publ-,c3078776
https://mb.cision.com/Main/15771/3078776/1222391.pdf
(c) 2020 Cision. All rights reserved., source